Closed

Virus Specific T Cell (VST) Technology

At Creative Biolabs, we are focused on our clients, and passionate about our role in providing the most valuable solutions to maximize the success of our clients. We have developed a series of solutions to support your cellular and gene therapy product candidates, including one-stop CAR-T therapy, TCR-T therapy, etc. To overcome the obstacles presented by immunosuppressive tumor microenvironment, we developed virus specific T cell (VST) technology to build more effective T cells.

Our Inspiration

Our natural anti-viral immunity is characterized by precision, potency and persistence. We utilize these features to develop our VST technology that can be used in the cure for cancer. Our understanding of the natural anti-viral immune response is employed to design the innovative cancer therapy. Our VST technology helps to create a sustained anti-cancer immune response. “Successful anti-cancer immunotherapy mimic core characteristics of the natural anti-viral immune response.”

Virus Specific T Cell (VST) Technology

Virus Specific T Cell (VST) Technology

Our born immune system can provide protection from viral infection that exists or may exist in the future. Virus specific T cells (VSTs) are critical for providing protection against many types of viruses which could potentially cause disease. These cells have the capability of infected cells’ recognition and killing, which is coordinated by other parts of immune system. VSTs persist in the infection environment and activate a rapid immune response once encountering viral antigens. Here are processes of VSTs treatment to kill viral infected cells.

  • Infected cells display viral antigens on cell surface
  • VSTs generation
  • VSTs recognize and bind to viral antigens
  • VSTs secret cytotoxic effects and induce cell death

Advantages

VST technology shows clinical safety and efficacy in treating solid tumor, and VSTs can overcome key limitations faced by other traditional T cell therapies.

  • Target specificity-limited toxicity
  • High tumor penetrance-better efficacy
  • Polyclonality-lower chance of tumor escape
  • Memory and durability-stronger persistence
  • Strong solid tumor efficacy
  • Excellent safety profile

How VST can be Involved in Your Project

CAR-VST

Creative Biolabs offers CAR-VST development to enhance safety, durability, and persistence compared with conventional CAR-T cells. We provide a wide range of CARs to recognize various cancer types.

Virus Specific T Cell VST Technology.
OV-VST

Creative Biolabs offers our clients with the combinational therapy - oncolytic viruses and VSTs to boost the innate and adaptive immune response against cancers.

Virus Specific T Cell VST Technology.
Others

If you have any other interests in VST technology such as combination with checkpoint inhibitor, etc., please contact us for more discussions.

Virus Specific T Cell VST Technology.


Highlight Features

  • Our VST technology is focused on making use of viruses as a driver for cancer treatment. Our collaborative approach and deep scientific understanding of your project help us shape the best strategy for bringing the cutting-edge technology to facilitate your program that reduces risk and accelerate timelines.
  • Our mission, our excellent scientists and our strong sense of purpose guide us in all we do to help our clients to reach their goals with high efficiency and great value.

We are proud to partner with our clients on their journey of novel therapy innovations. Creative Biolabs is committed to offering the most comprehensive, integrated portfolio to facilitate your drug development. If you have any interests in our solutions or techniques, please don’t hesitate to contact us to learn how we can be involved in your project.

Reference

  1. Ahmed, Nabil, et al. "Her2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial." JAMA oncology 3.8 (2017): 1094-1101.
  2. Bollard, Catherine M., et al. "Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma." J Clin Oncol 36.11 (2018): 1128-1139.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.